{"id":"unfixed-latanoprost-and-timolol","safety":{"commonSideEffects":[{"rate":"null","effect":"Blepharitis"},{"rate":"null","effect":"Eyelid skin darkening"},{"rate":"null","effect":"Itching"},{"rate":"null","effect":"Redness of the eyes"},{"rate":"null","effect":"Dry mouth"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Latanoprost works by mimicking the action of a natural prostaglandin in the eye, leading to increased outflow of fluid and decreased intraocular pressure. Timolol, on the other hand, blocks the action of beta-adrenergic receptors in the eye, reducing the production of aqueous humor and subsequently lowering intraocular pressure.","oneSentence":"Latanoprost is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:41.050Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT00219596","phase":"PHASE3","title":"Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-06","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":240},{"nctId":"NCT01281020","phase":"","title":"Adherence With Fixed Versus Unfixed Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-05","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension, Exfoliation Glaucoma","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"unfixed Latanoprost and Timolol","genericName":"unfixed Latanoprost and Timolol","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Latanoprost is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}